1. Home
  2. TECX vs DOMO Comparison

TECX vs DOMO Comparison

Compare TECX & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • DOMO
  • Stock Information
  • Founded
  • TECX 2019
  • DOMO 2010
  • Country
  • TECX United States
  • DOMO United States
  • Employees
  • TECX N/A
  • DOMO N/A
  • Industry
  • TECX
  • DOMO Computer Software: Prepackaged Software
  • Sector
  • TECX
  • DOMO Technology
  • Exchange
  • TECX Nasdaq
  • DOMO Nasdaq
  • Market Cap
  • TECX 334.4M
  • DOMO 436.2M
  • IPO Year
  • TECX 2018
  • DOMO 2018
  • Fundamental
  • Price
  • TECX $20.16
  • DOMO $14.01
  • Analyst Decision
  • TECX Buy
  • DOMO Hold
  • Analyst Count
  • TECX 6
  • DOMO 6
  • Target Price
  • TECX $78.67
  • DOMO $12.17
  • AVG Volume (30 Days)
  • TECX 239.7K
  • DOMO 709.1K
  • Earning Date
  • TECX 08-13-2025
  • DOMO 05-21-2025
  • Dividend Yield
  • TECX N/A
  • DOMO N/A
  • EPS Growth
  • TECX N/A
  • DOMO N/A
  • EPS
  • TECX N/A
  • DOMO N/A
  • Revenue
  • TECX N/A
  • DOMO $317,052,000.00
  • Revenue This Year
  • TECX N/A
  • DOMO $1.71
  • Revenue Next Year
  • TECX N/A
  • DOMO $2.43
  • P/E Ratio
  • TECX N/A
  • DOMO N/A
  • Revenue Growth
  • TECX N/A
  • DOMO N/A
  • 52 Week Low
  • TECX $13.70
  • DOMO $6.01
  • 52 Week High
  • TECX $61.07
  • DOMO $14.83
  • Technical
  • Relative Strength Index (RSI)
  • TECX 45.05
  • DOMO 62.53
  • Support Level
  • TECX $19.25
  • DOMO $12.36
  • Resistance Level
  • TECX $20.75
  • DOMO $14.53
  • Average True Range (ATR)
  • TECX 1.39
  • DOMO 0.70
  • MACD
  • TECX -0.21
  • DOMO -0.10
  • Stochastic Oscillator
  • TECX 28.15
  • DOMO 76.17

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

Share on Social Networks: